NASDAQ · APRE

Aprea Therapeutics, Inc.

Healthcare · Biotechnology

$0.74▼ 3.01% ($0.02)at close

Pre-market$0.77▲ 4.48%4:00 AM ET

52-week

$0.55$1.69

Market cap

$9.13M

P/E

-0.57

EPS (TTM)

-$0.23

Next earnings

Nov 11, 2026

Data caution

Per-share valuation inputs need verification

Event dated Jun 30, 2026

Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by 157.63%/yr over the past 1 years.

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.74

Estimated value / share

Unavailable

Base scenario

USD

Need current revenue and shares outstanding to build the revenue-driven FCFF model.

Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth — · Ending margin — · Discount rate 13.91%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 22, 2026, 9:55 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -49.86%Revenue (TTM): -100%FCF (TTM): 4.38%

What changed

The stock fell 49.86% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 4.38% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Revenue declined 100% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments.

CEOOren Gilad

SectorHealthcare

IndustryBiotechnology

Employees8

IPO dateOct 3, 2019

https://www.aprea.com

Market multiples

Forward P/E—

EV/EBITDA0.72

Enterprise value-$9.02M

Stock splits

Feb 13, 2023↓ Reverse

Every 20 shares became 1

-95%

Profitability & growth

Revenue growth-100%

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-47.44%▲31.9ppvs FY2025

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.08 · Revenue est $307.5K

View

NASDAQ · APRE

Aprea Therapeutics, Inc.

Healthcare · Biotechnology

$0.74▼ 3.01% ($0.02)at close

Pre-market$0.77▲ 4.48%4:00 AM ET

52-week

$0.55$1.69

Market cap

$9.13M

P/E

-0.57

EPS (TTM)

-$0.23

Next earnings

Nov 11, 2026

Data caution

Per-share valuation inputs need verification

Event dated Jun 30, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by 157.63%/yr over the past 1 years.

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.74

Estimated value / share

Unavailable

Base scenario

USD

Need current revenue and shares outstanding to build the revenue-driven FCFF model.

Year 1 growth — · Ending margin — · Discount rate 13.91%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 22, 2026, 9:55 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -49.86%Revenue (TTM): -100%FCF (TTM): 4.38%

What changed

The stock fell 49.86% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 4.38% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Performance

Return analysis

Company profile

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments.

CEOOren Gilad

SectorHealthcare

IndustryBiotechnology

Employees8

IPO dateOct 3, 2019

https://www.aprea.com

Market multiples

Forward P/E—

EV/EBITDA0.72

Enterprise value-$9.02M

Stock splits

Feb 13, 2023↓ Reverse

Every 20 shares became 1

-95%

Profitability & growth

Revenue growth-100%

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-47.44%▲31.9ppvs FY2025

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.08 · Revenue est $307.5K

View